Valeria Santini

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4999859/publications.pdf

Version: 2024-02-01

282	12,161	41344	30922
papers	citations	49 h-index	102 g-index

288	288	288	9416
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncology, The, 2009, 10, 223-232.	10.7	2,404
2	Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia. Journal of Clinical Oncology, 2010, 28, 562-569.	1.6	886
3	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nature Medicine, 2020, 26, 1549-1556.	30.7	372
4	Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib. Journal of the National Cancer Institute, 2011, 103, 553-561.	6.3	362
5	Changes in DNA Methylation in Neoplasia: Pathophysiology and Therapeutic Implications. Annals of Internal Medicine, 2001, 134, 573.	3.9	351
6	Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. New England Journal of Medicine, 2020, 382, 140-151.	27.0	335
7	Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. , 2022, 1, .		259
8	TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia, 2019, 33, 1747-1758.	7.2	195
9	Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. Journal of Clinical Oncology, 2016, 34, 2988-2996.	1.6	190
10	Homoharringtonine. Cancer, 2001, 92, 1591-1605.	4.1	177
11	Continued azacitidine therapy beyond time of first response improves quality of response in patients with higherâ€risk myelodysplastic syndromes. Cancer, 2011, 117, 2697-2702.	4.1	169
12	Autonomous Proliferation of Leukemic Cells in Vitro as a Determinant of Prognosis in Adult Acute Myeloid Leukemia. New England Journal of Medicine, 1993, 328, 614-619.	27.0	168
13	Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Annals of Oncology, 2018, 29, iv96-iv110.	1.2	158
14	Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. Journal of Clinical Investigation, 2015, 125, 1857-1872.	8.2	151
15	Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica, 2008, 93, 41-48.	3.5	146
16	Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. Lancet Haematology,the, 2017, 4, e127-e136.	4.6	132
17	Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. Journal of Clinical Oncology, 2021, 39, 1223-1233.	1.6	127
18	Histone Deacetylase Inhibitors: Molecular and Biological Activity as a Premise to Clinical Application. Current Drug Metabolism, 2007, 8, 383-394.	1.2	126

#	Article	IF	Citations
19	A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica, 2013, 98, 1067-1072.	3.5	120
20	Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. Blood Advances, 2018, 2, 923-932.	5.2	114
21	Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leukemia Research, 2010, 34, 1576-1588.	0.8	112
22	Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*. European Journal of Haematology, 2010, 85, 130-138.	2.2	111
23	Effects of azacitidine compared with conventional care regimens in elderly (â‰¥75 years) patients with higher-risk myelodysplastic syndromes. Critical Reviews in Oncology/Hematology, 2010, 76, 218-227.	4.4	108
24	Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2014, 25, iii57-iii69.	1.2	108
25	Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes. Clinical Cancer Research, 2009, 15, 5002-5007.	7.0	103
26	Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. Leukemia, 2018, 32, 2546-2557.	7.2	101
27	A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-Î± in anemic patients with low-risk MDS. Leukemia, 2018, 32, 2648-2658.	7.2	100
28	The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. Blood Advances, 2018, 2, 1765-1772.	5.2	100
29	Azacitidine for the treatment of lower risk myelodysplastic syndromes. Cancer, 2010, 116, 1485-1494.	4.1	98
30	Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials. Blood, 2019, 133, 1020-1030.	1.4	98
31	Hepcidin Levels and Their Determinants in Different Types of Myelodysplastic Syndromes. PLoS ONE, 2011, 6, e23109.	2.5	95
32	Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults. HemaSphere, 2018, 2, e150.	2.7	91
33	Deferasirox for transfusionâ€dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (<scp>GIMEMA MDS</scp>0306 <scp>T</scp>rial). European Journal of Haematology, 2014, 92, 527-536.	2.2	90
34	Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee. Blood, 2015, 126, 907-907.	1.4	85
35	Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine. Leukemia, 2014, 28, 621-628.	7.2	80
36	Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusionâ€“Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study. Journal of Clinical Oncology, 2021, 39, 48-56.	1.6	80

#	Article	IF	Citations
37	Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. Journal of Clinical Oncology, 2017, 35, 1591-1597.	1.6	79
38	Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. EBioMedicine, 2018, 31, 174-181.	6.1	72
39	Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?. Blood, 2013, 122, 2286-2288.	1.4	67
40	Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. Lancet Haematology,the, 2015, 2, e417-e426.	4.6	64
41	Why methylation is not a marker predictive of response to hypomethylating agents. Haematologica, 2014, 99, 613-619.	3.5	61
42	How I treat MDS after hypomethylating agent failure. Blood, 2019, 133, 521-529.	1.4	61
43	Proliferation Signaling and Activation of Shc, p21Ras, and Myc Via Tyrosine 764 of Human Granulocyte Colony-Stimulating Factor Receptor. Blood, 1998, 91, 1924-1933.	1.4	60
44	Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. Haematologica, 2011, 96, 1457-1461.	3.5	58
45	A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. Leukemia, 2018, 32, 413-418.	7.2	58
46	The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions. Blood, 2018, 132, 1-1.	1.4	57
47	Dnmt3a regulates myeloproliferation and liver-specific expansion of hematopoietic stem and progenitor cells. Leukemia, 2016, 30, 1133-1142.	7.2	56
48	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. Lancet Haematology,the, 2020, 7, e601-e612.	4.6	56
49	A variant erythroferrone disrupts iron homeostasis in SF3B1 -mutated myelodysplastic syndrome. Science Translational Medicine, 2019, 11, .	12.4	55
50	Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes. Clinical Cancer Research, 2019, 25, 6976-6985.	7.0	55
51	High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study. Leukemia and Lymphoma, 2013, 54, 658-661.	1.3	54
52	Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. Leukemia, 2017, 31, 2449-2457.	7.2	51
53	Practical use of azacitidine in higher-risk myelodysplastic syndromes: An expert panel opinion. Leukemia Research, 2010, 34, 1410-1416.	0.8	50
54	Outcome of therapy-related myeloid neoplasms treated with azacitidine. Journal of Hematology and Oncology, 2012, 5, 44.	17.0	49

#	Article	IF	Citations
55	Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes. Journal of Clinical Oncology, 2021, 39, 1426-1436.	1.6	49
56	Amifostine: chemotherapeutic and radiotherapeutic protective effects. Expert Opinion on Pharmacotherapy, 2001, 2, 479-489.	1.8	47
57	Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients. Leukemia Research, 2004, 28, 367-372.	0.8	46
58	Iron overload and chelation therapy in myelodysplastic syndromes. Critical Reviews in Oncology/Hematology, 2014, 91, 64-73.	4.4	46
59	Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells. Oncogene, 2008, 27, 1767-1778.	5.9	44
60	Clinical Use of Erythropoietic Stimulating Agents in Myelodysplastic Syndromes. Oncologist, 2011, 16, 35-42.	3.7	44
61	Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study. Lancet Haematology,the, 2018, 5, e393-e402.	4.6	44
62	Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML. Blood Advances, 2022, 6, 5132-5145.	5.2	43
63	Treatment of low-risk myelodysplastic syndromes. Hematology American Society of Hematology Education Program, 2016, 2016, 462-469.	2.5	41
64	Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?. Haematologica, 2016, 101, e280-e283.	3.5	41
65	The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma. British Journal of Haematology, 2008, 141, 814-819.	2.5	40
66	Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-Azacytidine. Leukemia, 2011, 25, 1910-1913.	7.2	40
67	Anemia as the Main Manifestation of Myelodysplastic Syndromes. Seminars in Hematology, 2015, 52, 348-356.	3.4	40
68	In vitro chemosensitivity testing of leukemic cells: Prediction of response to chemotherapy in patients with acute non-lymphocytic leukemia. Hematological Oncology, 1989, 7, 287-293.	1.7	39
69	Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML. Leukemia, 2019, 33, 205-216.	7.2	39
70	Butyrates, as a single drug, induce histone acetylation and granulocytic maturation: possible selectivity on core binding factor-acute myeloid leukemia blasts. Cancer Research, 2003, 63, 8955-61.	0.9	39
71	Quality of life and physicians' perception in myelodysplastic syndromes. American Journal of Blood Research, 2012, 2, 136-47.	0.6	37
72	Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups. Haematologica, 2013, 98, 1344-1352.	3.5	35

#	Article	IF	Citations
73	Sequential Cis-Platinum and Fludarabine with or without Arabinosyl Cytosine in Patients Failing Prior Fludarabine Therapy for Chronic Lymphocytic Leukemia: A Phase II Study. Leukemia and Lymphoma, 1999, 36, 57-65.	1.3	33
74	A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q). Leukemia, 2013, 27, 1610-1613.	7.2	31
75	Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusionâ€“dependent anemia and thrombocytopenia. BMC Hematology, 2016, 16, 12.	2.6	31
76	Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide. Leukemia, 2016, 30, 2405-2409.	7.2	31
77	Induction of granulocytic maturation in acute myeloid leukemia by G-CSF and retinoic acid. Leukemia Research, 1991, 15, 341-350.	0.8	29
78	Distinct Signal Transduction Abnormalities and Erythropoietin Response in Bone Marrow Hematopoietic Cell Subpopulations of Myelodysplastic Syndrome Patients. Clinical Cancer Research, 2012, 18, 3079-3089.	7.0	29
79	Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment. Blood Cancer Journal, 2015, 5, e347-e347.	6.2	29
80	Inherited thrombocytopenia caused by ANKRD26 mutations misdiagnosed and treated as myelodysplastic syndrome: report on two cases. Journal of Thrombosis and Haemostasis, 2017, 15, 2388-2392.	3.8	29
81	Comparative Proteomic Analysis of Chronic Myelogenous Leukemia Cells:â€‰Inside the Mechanism of Imatinib Resistance. Journal of Proteome Research, 2007, 6, 367-375.	3.7	28
82	Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib. Leukemia Research, 2011, 35, 1164-1169.	0.8	28
83	Pro-inflammatory proteins S100A9 and tumor necrosis factor-Î± suppress erythropoietin elaboration in myelodysplastic syndromes. Haematologica, 2017, 102, 2015-2020.	3.5	28
84	Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations. Leukemia Research, 2014, 38, 1381-1391.	0.8	27
85	Searching for the Magic Bullet Against Cancer: The Butyrate Saga. Leukemia and Lymphoma, 2001, 42, 275-289.	1.3	26
86	Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts. Annals of Hematology, 2005, 84, 54-60.	1.8	26
87	Epigenetics in focus: Pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents. Critical Reviews in Oncology/Hematology, 2013, 88, 231-245.	4.4	26
88	Hypomethylating agents in the treatment of acute myeloid leukemia: A guide to optimal use. Critical Reviews in Oncology/Hematology, 2019, 140, 1-7.	4.4	26
89	Novel therapeutic strategies: hypomethylating agents and beyond. Hematology American Society of Hematology Education Program, 2012, 2012, 65-73.	2.5	26
90	Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes. , 2014, 86, 207-215.		25

#	Article	IF	Citations
91	Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS). Leukemia Research, 2017, 52, 50-57.	0.8	25
92	Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells. Epigenetics, 2013, 8, 210-219.	2.7	24
93	Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes. Blood Advances, 2021, 5, 2216-2228.	5.2	24
94	Decitabine Versus Hydroxyurea for Advanced Proliferative CMML: Results of the Emsco Randomized Phase 3 Dacota Trial. Blood, 2020, 136, 53-54.	1.4	24
95	In vitro chemosensitivity testing of leukemic cells: Development of a semiautomated colorimetric assay. Hematological Oncology, 1989, 7, 243-253.	1.7	23
96	DIFFERENTIATION THERAPY OF MYELODYSPLASTIC SYNDROMES: FACT OR FICTION?. British Journal of Haematology, 1998, 102, 1124-1138.	2.5	23
97	Ironâ€chelating therapy with deferasirox in transfusionâ€dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study. British Journal of Haematology, 2017, 177, 741-750.	2.5	23
98	Susceptibility of acute myeloid leukemia (AML) cells from clinically resistant and sensitive patients to daunomycin (DNR): Assessment in vitro after stimulation with colony stimulating factors (CSFs). Leukemia Research, 1990, 14, 377-380.	0.8	22
99	Functional and structural interactions between osteoblastic and preosteoclastic cells in vitro. Cell and Tissue Research, 1995, 281, 33-42.	2.9	22
100	Regioselective synthesis and biological profiling of butyric and phenylalkylcarboxylic esters derivated from D-mannose and xylitol: influence of alkyl chain length on acute toxicity. European Journal of Pharmaceutical Sciences, 1999, 7, 93-106.	4.0	22
101	Primary human acute myeloblastic leukaemia: an analysis of in vitro granulocytic maturation following stimulation with retinoic acid and G-CSF. British Journal of Haematology, 1991, 79, 382-389.	2.5	21
102	Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes. , 2014, , n/a-n/a.		21
103	Effects of fludarabine and gemcitabine on human acute myeloid leukemia cell line HL 60: Direct comparison of cytotoxicity and cellular Ara-C uptake enhancement. Leukemia Research, 1996, 20, 37-45.	0.8	20
104	Butyrateâ€stable monosaccharide derivatives induce maturation and apoptosis in human acute myeloid leukaemia cells. British Journal of Haematology, 1998, 101, 529-538.	2.5	20
105	The carboxy-terminal region of the granulocyte colony-stimulating factor receptor transduces a phagocytic signal. Blood, 2003, 101, 4615-4622.	1.4	20
106	ITACA: A new validated international erythropoietic stimulating agentâ€response score that further refines the predictive power of previous scoring systems. American Journal of Hematology, 2017, 92, 1037-1046.	4.1	20
107	Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. Leukemia Research, 2018, 73, 51-57.	0.8	20
108	The STIMULUS Program: Clinical Trials Evaluating Sabatolimab (MBG453) Combination Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) or Acute Myeloid Leukemia (AML). Blood, 2020, 136, 45-46.	1.4	20

#	Article	IF	Citations
109	The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS). Blood, 2008, 112, 227-227.	1.4	20
110	Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): Consensus statements and report from an expert workshop. Leukemia Research, 2012, 36, 264-270.	0.8	19
111	Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine. Leukemia Research, 2012, 36, 607-618.	0.8	19
112	Updated recommendations on the management of gastrointestinal disturbances during iron chelation therapy with Deferasirox in transfusion dependent patients with myelodysplastic syndrome â€“ Emphasis on optimized dosing schedules and new formulations. Leukemia Research, 2015, 39, 1028-1033.	0.8	19
113	Somatostatin and its cyclic octapeptide analog SMS 201â€“995 as inhibitors of proliferation of human acute lymphoblastic and acute myeloid leukemia. Leukemia Research, 1995, 19, 707-712.	0.8	17
114	Coexpression of erythroid and megakaryocytic genes in acute erythroblastic (FAB M6) and megakaryoblastic (FAB M7) leukaemias. British Journal of Haematology, 1998, 102, 1335-1337.	2.5	17
115	TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes. Blood, 2019, 134, 675-675.	1.4	17
116	Quality of Life in Myelodysplastic Syndromes and Physicians' Perception.. Blood, 2009, 114, 3822-3822.	1.4	17
117	Dependence of leukemic cell autofluorescence patterns on the degree of differentiation. Photochemical and Photobiological Sciences, 2003, 2, 981.	2.9	16
118	Redistribution of H3K27me3 and acetylated histone H4 upon exposure to azacitidine and decitabine results in de-repression of the AML1/ETO target geneIL3. Epigenetics, 2014, 9, 387-395.	2.7	16
119	Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy. BMJ Supportive and Palliative Care, 2016, 6, 80-88.	1.6	16
120	Novel therapeutic strategies: hypomethylating agents and beyond. Hematology American Society of Hematology Education Program, 2012, 2012, 65-73.	2.5	16
121	Genetic lesions associated with blastic transformation of polycythemia vera and essential thrombocythemia. Genes Chromosomes and Cancer, 1997, 19, 250-255.	2.8	15
122	Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis. British Journal of Haematology, 2016, 175, 975-979.	2.5	15
123	Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care. Blood Cancer Journal, 2017, 7, 644.	6.2	15
124	The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 136-144.e7.	0.4	15
125	Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations. Blood Reviews, 2019, 34, 16-25.	5.7	15
126	Hypermethylation of Wnt antagonist gene promoters and activation of Wnt pathway in myelodysplastic marrow cells. Leukemia Research, 2012, 36, 1290-1295.	0.8	14

#	Article	IF	Citations
127	Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine. Leukemia Research, 2017, 63, 72-77.	0.8	14
128	Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7. Leukemia, 2020, 34, 2441-2450.	7.2	14
129	Phase 2 Study of Monotherapy Galunisertib (LY2157299 Monohydrate) in Very Low-, Low-, and Intermediate-Risk Patients with Myelodysplastic Syndromes. Blood, 2015, 126, 1669-1669.	1.4	14
130	Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients. American Journal of Hematology, 2010, 85, 960-963.	4.1	13
131	Acetylome and phosphoproteome modifications in imatinib resistant chronic myeloid leukaemia cells treated with valproic acid. Leukemia Research, 2011, 35, 921-931.	0.8	13
132	Treatment of Myelodysplastic Syndrome with Thrombomimetic Drugs. Seminars in Hematology, 2015, 52, 38-45.	3.4	13
133	Azacitidine: activity and efficacy as an epigenetic treatment of myelodysplastic syndromes. Expert Review of Hematology, 2009, 2, 121-127.	2.2	12
134	Azacitidine in lower-risk myelodysplastic syndromes. Leukemia Research, 2009, 33, S22-S26.	0.8	12
135	The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply). Haematologica, 2011, 96, e23-e24.	3.5	12
136	Guideline-based indicators for adult patients with myelodysplastic syndromes. Blood Advances, 2020, 4, 4029-4044.	5.2	12
137	Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients. Leukemia, 2021, 35, 897-900.	7.2	12
138	Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial. Blood, 2022, 139, 624-629.	1.4	12
139	Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance. Blood, 2007, 110, 4620-4621.	1.4	11
140	Hematologic Improvement-Neutrophil and -Platelet in the MEDALIST Trial: Multilineage Data from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions. Blood, 2019, 134, 4243-4243.	1.4	11
141	Efficacy and Safety of Lenalidomide (LEN) Versus Placebo (PBO) in RBC-Transfusion Dependent (TD) Patients (Pts) with IPSS Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (MDS) without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (ESAs): Results from a Randomized Phase 3 Study (CC-5013-MDS-005). Blood, 2014, 124, 409-409.	1.4	11
142	Treatment of Low-Risk Myelodysplastic Syndrome: Hematopoietic Growth Factors Erythropoietins and Thrombopoietins. Seminars in Hematology, 2012, 49, 295-303.	3.4	10
143	In elderly patients with AML, which patients should be considered fit or unfit for standard induction therapy?. Hematology American Society of Hematology Education Program, 2012, 2012, 74-75.	2.5	10
144	Influence of Karyotype On Overall Survival in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Azacitidine or a Conventional Care Regimen.. Blood, 2009, 114, 1755-1755.	1.4	10

#	Article	IF	Citations
145	Efficacy and Safety of Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Analysis of a Prospective, Randomized, Single-Blind, Placebo-Controlled Trial (EQoL-MDS). Blood, 2012, 120, 923-923.	1.4	10
146	Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 236-250.	0.4	10
147	Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial. Journal of Clinical Medicine, 2022, 11, 27.	2.4	10
148	Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes. Haematologica, 2002, 87, 322-3.	3.5	10
149	Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study. Haematologica, 2019, 104, e4-e8.	3.5	9
150	Iron overload alters the energy metabolism in patients with myelodysplastic syndromes: results from the multicenter FISM BIOFER study. Scientific Reports, 2020, 10, 9156.	3.3	9
151	Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive. Blood, 2018, 132, 463-463.	1.4	9
152	The Commands Trial: A Phase 3 Study of the Efficacy and Safety of Luspatercept Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low-, Low-, or Intermediate-Risk MDS in Erythropoiesis Stimulating Agent-Naive Patients Who Require RBC Transfusions. Blood, 2020, 136, 1-2.	1.4	9
153	Hypocellular myelodysplastic syndromes (h-MDS): from clinical description to immunological characterization in the Italian multi-center experience. Leukemia, 2022, 36, 1947-1950.	7.2	9
154	The c-Jun-N-terminal-Kinase inhibitor SP600125 enhances the butyrate derivative D1-induced apoptosis via caspase 8 activation in Kasumi 1 t(8;21) acute myeloid leukaemia cells. British Journal of Haematology, 2006, 135, 653-659.	2.5	8
155	Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine. Leukemia and Lymphoma, 2013, 54, 1786-1787.	1.3	8
156	Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes. British Journal of Haematology, 2014, 165, 49-56.	2.5	8
157	Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with secondâ€generation tyrosine kinase inhibitors. American Journal of Hematology, 2011, 86, 523-525.	4.1	7
158	Hypomethylating agents and chemotherapy in MDS. Best Practice and Research in Clinical Haematology, 2013, 26, 411-419.	1.7	7
159	A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria. Cytometry Part B - Clinical Cytometry, 2013, 84B, 71-81.	1.5	7
160	First-line Therapeutic Strategies for Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S31-S36.	0.4	7
161	SARSâ€CoVâ€2Âin Myelodysplastic Syndromes: A Snapshot From Early Italian Experience. HemaSphere, 2020, 4, e483.	2.7	7
162	Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (Pts) with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions. Blood, 2019, 134, 841-841.	1.4	7

#	Article	IF	Citations
163	Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial. Blood, 2019, 134, 3000-3000.	1.4	7
164	Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the Medalist Study. Blood, 2020, 136, 13-15.	1.4	7
165	Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Results on Efficacy, Safety and Quality of Life of an International, Multicenter Prospective, Randomized, Trial. Blood, 2015, 126, 91-91.	1.4	7
166	Severe hypoxia selects hematopoietic progenitors with stem cell potential from primary Myelodysplastic syndrome bone marrow cell cultures. Oncotarget, 2018, 9, 10561-10571.	1.8	7
167	The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia. Advances in Therapy, 2022, 39, 1474-1488.	2.9	7
168	Life after hypomethylating agents in myelodysplastic syndrome. Current Opinion in Hematology, 2015, 22, 155-162.	2.5	6
169	Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study. Biology of Blood and Marrow Transplantation, 2018, 24, 1754-1758.	2.0	6
170	Advances in myelodysplastic syndrome. Current Opinion in Oncology, 2021, 33, 681-686.	2.4	6
171	Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the Medalist Study. Blood, 2020, 136, 10-12.	1.4	6
172	Impact Of Cytogenetics and Cytogenetic Response On Outcome In Myelodysplastic Syndromes (MDS) treated With Azacitidine (AZA). A Collaborative Study In 878 Patients. Blood, 2013, 122, 389-389.	1.4	6
173	In vitro antileukemic effect of a new anthracycline analogue, MEN 11079. Leukemia Research, 2003, 27, 1125-1134.	0.8	5
174	Challenges of phase III trial design for novel treatments in diseases with no standard treatment: The AZA-001 myelodysplasia study model. Leukemia Research, 2014, 38, 258-262.	0.8	5
175	Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial. Leukemia and Lymphoma, 2018, 59, 2135-2143.	1.3	5
176	Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity scoreâ€matched analysis. Cancer Medicine, 2019, 8, 7567-7576.	2.8	5
177	Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes. Blood, 2018, 132, 1797-1797.	1.4	5
178	Azacitidine Prolongs Overall Survival (OS) and Reduces Infections and Hospitalizations in Patients (Pts) with WHO-Defined Acute Myeloid Leukemia (AML) Compared with Conventional Care Regimens (CCR). Blood, 2008, 112, 3636-3636.	1.4	5
179	Achievement of Red Blood Cell (RBC) Transfusion Independence with Azacitidine (AZA) Leads to Improved Survival In Patients with Higher-Risk Myelodysplasias Regardless of Baseline Transfusion Needs. Blood, 2010, 116, 1856-1856.	1.4	5
180	Deferasirox Chelation Therapy in Transfusion Dependent MDS Patients. Final Report From the Gimema MDS0306 Prospective Trial. Blood, 2012, 120, 425-425.	1.4	5

#	Article	IF	Citations
181	The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort. Blood, 2016, 128, 1063-1063.	1.4	5
182	Targeting ineffective hematopoiesis in myelodysplastic syndromes. American Journal of Hematology, 2022, 97, 171-173.	4.1	5
183	Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Leukemia, 2022, 36, 1432-1435.	7.2	5
184	In elderly patients with AML, which patients should be considered fit or unfit for standard induction therapy?. Hematology American Society of Hematology Education Program, 2012, 2012, 74-5.	2.5	5
185	Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents. Leukemia Research, 2020, 99, 106472.	0.8	4
186	Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels. Leukemia and Lymphoma, 2020, 61, 1475-1483.	1.3	4
187	Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment. Blood, 2020, 136, 17-17.	1.4	4
188	Management and Supportive Care Measures of Adverse Events (AEs) in Higher-Risk MDS Patients (Pts) Treated with Azacitidine (AZA).. Blood, 2008, 112, 1653-1653.	1.4	4
189	Lyn kinase is activated following thrombopoietin stimulation of the megakaryocytic cell line B1647. Haematologica, 2002, 87, 1242-7.	3.5	4
190	No Preferential Sensitivity of t(8;21) Acute Myeloid Leukemias to Cytosine Arabinoside in Vitro: Is Intensity of Therapy or High Dose Ara-C Crucial for Response?. Leukemia and Lymphoma, 2004, 45, 1361-1364.	1.3	3
191	Treatment Options in Myelodysplastic Syndromes: A New Frontier. Journal of Chemotherapy, 2008, 20, 291-296.	1.5	3
192	Haploidentical bone marrow transplantation in patients with advanced myelodysplastic syndrome. American Journal of Hematology, 2017, 92, E117-E119.	4.1	3
193	Of blood and bone: the sotatercept adventure. Lancet Haematology,the, 2018, 5, e54-e55.	4.6	3
194	Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a PhaseÂIIIÂTrial. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 213-219.e4.	0.4	3
195	Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial. Blood, 2019, 134, 2999-2999.	1.4	3
196	A Multicenter, Italian Trial of Early Iron Chelation Therapy with Low Dose Deferasirox (ExjadeÂ®) in Patients with Low/Intermediate-1 Risk MDS at the Beginning of Transfusional Story. Blood, 2019, 134, 4256-4256.	1.4	3
197	Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.. Blood, 2009, 114, 860-860.	1.4	3
198	High Predictive Value of the Revised International Prognostic Scoring System (IPSS-R): An External Analysis of 646 Patients From a Multiregional Italian MDS Registry. Blood, 2012, 120, 1702-1702.	1.4	3

#	Article	IF	Citations
199	Randomized, Placebo-Controlled, Phase I/II Trial Of The Thrombopoietin Receptor Agonist Eltrombopag In Thrombocytopenic Patients With Advanced Myelodysplastic Syndromes Or Acute Myeloid Leukemia â€" A Subgroup Analysis Of Patients Receiving Concomitant Anticancer Therapy. Blood, 2013, 122, 5214-5214.	1.4	3
200	Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Blood, 2016, 128, 2011-2011.	1.4	3
201	Myelodysplastic Syndromes with Hypocellular Marrow: Clinical Characteristics and Evaluation of Outcome. Blood, 2018, 132, 1829-1829.	1.4	3
202	On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs). Blood, 2021, 138, 2598-2598.	1.4	3
203	Iron-mediated tissue damage in acquired ineffective erythropoiesis disease: Itâ€™s more a matter of burden or more of exposure to toxic iron form?. Leukemia Research, 2022, 114, 106792.	0.8	3
204	Impact of Lenalidomide Treatment on Overall Survival in Patients With Lower-Risk, Transfusion-Dependent Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e874-e883.	0.4	3
205	Proliferation and cell loss of human leukemic cell subpopulations in liquid culture. Experientia, 1988, 44, 245-247.	1.2	2
206	Induction of Differentiation of HL-60 Cells Along the Monocytic Pathway by 5-Methyltetrahydrofolate. Journal of Chemotherapy, 1989, 1, 359-364.	1.5	2
207	Hemolymphangiomatosis of the Spleen. Journal of Computer Assisted Tomography, 2005, 29, 831-833.	0.9	2
208	Mutated ASXL1 and number of somatic mutations as possible indicators of progression to chronic myelomonocytic leukemia of myelodysplastic syndromes with single or multilineage dysplasia. Haematologica, 2017, 102, e332-e335.	3.5	2
209	Enasidenib: a magic bullet for myelodysplastic syndromes?. Lancet Haematology,the, 2020, 7, e275-e276.	4.6	2
210	Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice. Cancer, 2021, 127, 2015-2024.	4.1	2
211	Activity of Vinorelbine on B-Chronic Lymphocytic Leukemia Cells In Vitro. Advances in Experimental Medicine and Biology, 1999, 457, 473-476.	1.6	2
212	Abnl Marro: An International Cooperative Trial for Patients with MDS/MPN Overlap Syndromes. Blood, 2019, 134, 4273-4273.	1.4	2
213	5-Azacytidine for the Treatment of Acute Myeloid Leukemia: A Retrospective, Multicenter Study of 55 Patients.. Blood, 2008, 112, 1947-1947.	1.4	2
214	Low-Dose Dasatinib as Front-Line Therapy for Elderly (> 60 Years) Patients with CML. Blood, 2010, 116, 2293-2293.	1.4	2
215	The Proinflammatory Protein S100A9 Suppresses Erythropoietin Elaboration in Patients with Myelodysplastic Syndromes. Blood, 2015, 126, 355-355.	1.4	2
216	The Safety and Tolerability of Azacitidine (AZA) Are Comparable in Patients with Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndromes (MDS). Blood, 2015, 126, 3754-3754.	1.4	2

#	Article	IF	Citations
217	Comprehensive Inflammatory Cytokine Profiling Identifies IL-8/CXCL8 As Elevated, Associated with Proliferative Features, and Independently Prognostic in Chronic Myelomonocytic Leukemia (CMML). Blood, 2016, 128, 109-109.	1.4	2
218	Azacitidine (AZA) Prolongs Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) with Poor Prognostic Karyotypes Compared with Conventional Care Regimens (CCR). Blood, 2016, 128, 1638-1638.	1.4	2
219	Impact of Somatic Gene Mutations on Response to Lenalidomide (LEN) in IPSS Lower-Risk Myelodysplastic Syndromes (MDS) Patients (Pts) without Del(5q) and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents (ESAs). Blood, 2016, 128, 225-225.	1.4	2
220	Proliferation Signaling and Activation of Shc, p21Ras, and Myc Via Tyrosine 764 of Human Granulocyte Colony-Stimulating Factor Receptor. Blood, 1998, 91, 1924-1933.	1.4	2
221	Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment. Blood, 2019, 134, 4248-4248.	1.4	2
222	Effect of Luspatercept on Biomarkers of Erythropoiesis in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Medalist Trial. Blood, 2020, 136, 38-39.	1.4	2
223	Effect of (dl)-5-Methyltetrahydrofolate on Acute Non-Lymphocytic Leukemia Cells in Primary Culture. Journal of Chemotherapy, 1991, 3, 255-259.	1.5	1
224	A selective activity of DNMTi decitabine on AML1ETO positive cells?. Leukemia Research, 2007, 31, 741-742.	0.8	1
225	The quest for the perfect MDS scoring system. Leukemia Research, 2012, 36, 125-126.	0.8	1
226	Defeating anaemia in myelodysplastic syndromes: another step forward. Lancet Oncology, The, 2017, 18, 1290-1292.	10.7	1
227	Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions: Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 495-500.	0.4	1
228	Serum Inflamma-miR Signature: A Biomarker of Myelodysplastic Syndrome?. Frontiers in Oncology, 2020, 10, 595838.	2.8	1
229	Pretreatment Health-Related Quality of Life Profile According to the EORTC QLQ-C30 in Patients with Myelodysplastic Syndromes (MDS): Analysis on 443 Lower-Risk MDS Patients. Blood, 2018, 132, 2293-2293.	1.4	1
230	Comorbidities Indexes In Patients Treated with 5-Azacitidine Are a An Useful and Easily Applicable Tool to Refine Prognostic Evaluation. Blood, 2010, 116, 606-606.	1.4	1
231	An Observational Multicenter Study to Assess the Cost of Illness and Quality of Life in Patients with Myelodysplastic Syndromes in Italy. Blood, 2011, 118, 1023-1023.	1.4	1
232	Prognostic Factors of Response to Erythropoiesis Stimulating Agents (ESA) Treatment in Non RBC Transfusion Dependent Lower Risk MDS. Preliminary Results of a French and Italian Study (on behalf) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1	
233	A Real Life Survey On Erythropoietin Alpha Treatment In a Cohort Of 1049 Low Risk MDS Patients: An Italian MDS Registry Study. Blood, 2013, 122, 745-745.	1.4	1
234	Safety of Lenalidomide (LEN) 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS): Pooled Analysis of Treatment-Emergent Adverse Events (TEAEs). Blood, 2015, 126, 2880-2880.	1.4	1

#	Article	IF	Citations
235	5-Azacytidine, Valproic Acid and ALL-Trans Retinoic Acid in INT-2/High Risk Myelodysplastic Syndromes: Results of the GIMEMA MDS0205 Multicenter Trial. Blood, 2008, 112, 3648-3648.	1.4	1
236	Re-Evaluation of the Efficacy of Azacitidine (AZA) In Patients From the AZA-001 Study with Higher-Risk Myelodysplastic Syndromes (MDS) Classified by WHO Criteria and WPSS Risk. Blood, 2010, 116, 4031-4031.	1.4	1
237	Bone Marrow Hypocellularity Does Not Impair the Tolerability or Efficacy of Azacitidine (AZA) in Patients with Higher-Risk Myelodysplastic Syndromes Treated in the AZA-001 Study. Blood, 2012, 120, 3808-3808.	1.4	1
238	The Revised IPSS (IPSS-R) Predicts Response To Erythropoietic Stimulating agents (ESA) In Pts With Classical IPSS Low Or Intermediate-1 (int 1)- MDS: A Joint Retrospective Study Of The GFM, DÃ¼sseldorf Registry and Fism. Blood, 2013, 122, 2761-2761.	1.4	1
239	Decitabine In Advanced Chronic Myelomonocytic Leukemia. Blood, 2013, 122, 1573-1573.	1.4	1
240	Outcome of Lower Risk Non Del 5q MDS after Failure of Erythropoiesis Stimulating Agents (ESA), and Impact of Post-ESA Treatment on Survival: A Retrospective European Study. Blood, 2015, 126, 1665-1665.	1.4	1
241	Efficacy and Safety of Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Patients Aged â‰¥75 Years with Acute Myeloid Leukemia (AML) in the Phase 3 AZA-AML-001 Study. Blood, 2016, 128, 2818-2818.	1.4	1
242	Molecular Spectrum of CSF3R variants Correlate with Specific Myeloid Malignancies and Secondary Mutations. Blood, 2018, 132, 4389-4389.	1.4	1
243	Clonogenic growth of acute non-lymphocytic leukemia cells in serum-free medium. Experientia, 1988, 44, 903-906.	1.2	0
244	Natural Fluorescence Imaging of Leukemic Cells for Studying Uptake and Retention of Anthracyclines. Advances in Experimental Medicine and Biology, 1999, 457, 89-94.	1.6	0
245	Azacitidine in Myelodysplastic Syndromes. Drugs, 2005, 65, 1790-1791.	10.9	0
246	C003 Proliferative and apoptotic signalling in bone marrow cell subpopulations of myelodysplastic syndromes patients using flow-cytometry technique. Leukemia Research, 2009, 33, S32.	0.8	0
247	P077 Adaptation and changes in quality of life in patients with myelodysplastic syndrome. Leukemia Research, 2009, 33, S103.	0.8	0
248	P116 Azacitidine for the treatment of lower risk myelodysplastic syndromes: final results from an Italian named patient program. Leukemia Research, 2009, 33, S127.	0.8	0
249	P117 Monocentric evaluation of response and tolerability of subcutaneous azacitidine in elderly MDS patients with comorbidities. Leukemia Research, 2009, 33, S127-S128.	0.8	0
250	P127 Rates of infection and bleeding are not increased in patients (Pts) with MDS treated with azacitidine (AZA) compared with best supportive care (BSC). Leukemia Research, 2009, 33, S133.	0.8	0
251	P128 Transfusion independence (TI) in patients with myelodysplastic syndromes (MDS) treated with azacitidine (AZA). Leukemia Research, 2009, 33, S133-S134.	0.8	0
252	P138 Valproic acid at therapeutic plasma levels may increase 5-azacitidine efficacy in higher risk myelodysplastic syndromes. Leukemia Research, 2009, 33, S139-S140.	0.8	0

#	Article	IF	Citations
253	On Raising the â€œDust of Bloodâ€• From Unrevealing Thrombopoiesis to Treatment of Thrombocytopenias With Thrombomimetic Drugs. Seminars in Hematology, 2015, 52, 1-3.	3.4	0
254	Management of Lower Risk Non-del(5q) MDS. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S35-S36.	0.4	0
255	Does G6PD-Deficiency Related Oxidative Stress and Hemolysis Affect Erythroid Response to Erythropoietic Stimulating Agents (ESA) in Myelodysplastic Patients?. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S259.	0.4	0
256	Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. Leukemia and Lymphoma, 2019, 60, 246-249.	1.3	0
257	Clinical and Genetic Profiles of Young Adult Patients with Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S347.	0.4	0
258	Outcome of MDS, MDS/MPN Patients Aged <65 Treated with Hypomethylating Agents as a Bridge to Transplant in a Single Tertiary-Care Italian Center. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S346.	0.4	0
259	Quality of Life Assessment in Patients Affected by Myelodysplastic Syndrome. Blood, 2008, 112, 2363-2363.	1.4	0
260	5-Azacytidine in 82 Low/Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Results from the Italian Patient Named Program. Blood, 2008, 112, 2680-2680.	1.4	0
261	Retrospective Application of European LeukemiaNet Provisional Criteria for Second-Generation TKI Chronic Myeloid Leukemia. Blood, 2010, 116, 2270-2270.	1.4	0
262	Iron Chelation Therapy with Deferasirox In Transfusion Dependent Myelodysplastic Syndrome Patients. Preliminary Report From the Prospective MDS0306 GIMEMA Trial. Blood, 2010, 116, 2928-2928.	1.4	0
263	Hepcidin Levels and Their Determinants In Different Types of Myelodysplastic Syndromes. Blood, 2010, 116, 4250-4250.	1.4	0
264	Mechanism of Resistance to Azacitidine in Myelodisplastic Syndromes.. Blood, 2012, 120, 2810-2810.	1.4	0
265	Lenalidomide in Myelodysplastic Syndromes with 5q Deletion. Results From the Italian National Cancer Registry. Blood, 2012, 120, 3850-3850.	1.4	0
266	Severe Hypoxia Promotes Selection of Repopulating Progenitor CELLS in Primary MDS BONE Marrow CELL Culture. Blood, 2012, 120, 4747-4747.	1.4	0
267	ANTI-Leukemic Activity of DNA Methyltransferase Inhibitors Azacitidine and Decitabine On AML1-ETO Positive CELLS Is Evident At LOW Doses and Selectively Mediated by Epigenetic Mechanisms. Blood, 2012, 120, 4615-4615.	1.4	0
268	Health-Related Quality Of Life In Transfusion-Dependent Patients With Myelodysplastic Syndromes Treated With Deferasirox. A Multicenter Prospective Study. Blood, 2013, 122, 2980-2980.	1.4	0
269	Therapy-Related Myeloid Neoplasms: Report Of The Italian Network On Secondary Leukemias. Blood, 2013, 122, 2659-2659.	1.4	0
270	Molecular Determinants of Decitabine Response in Chronic Myelomonocytic Leukemia. Blood, 2014, 124, 4644-4644.	1.4	0

#	Article	IF	Citations
271	Distinct DNA Methylation and Expression Profiles Underlie CMML Responsiveness to Decitabine and Uncover Novel Mechanism of Resistance. Blood, 2014, 124, 4598-4598.	1.4	0
272	Age and Gender-Related Pretreatment Quality of Life Profiles in Patients with Higher-Risk Myelodysplastic Syndromes. Establishing Benchmark Data from an International Study. Blood, 2015, 126, 2099-2099.	1.4	0
273	Hypoxia Increases Repopulating Ability of Myelodysplastic Syndrome Bone Marrow Cells. Blood, 2015, 126, 4753-4753.	1.4	0
274	Clinical benefit among lenalidomide (LEN)-treated patients (pts) with RBC transfusion-dependent (RBC-TD) low-/int-1-risk myelodysplastic syndromes (MDS) without del(5q).. Journal of Clinical Oncology, 2016, 34, 7014-7014.	1.6	0
275	Treatment-emergent adverse events (TEAEs) in lenalidomide (LEN)-treated Low-/Int-1-risk myelodysplastic syndromes (MDS) patients (pts) without del(5q) ineligible for or refractory to erythropoiesis-stimulating agents (ESAs).. Journal of Clinical Oncology, 2016, 34, 7061-7061.	1.6	0
276	Resistance to Azacitidine Is Determined at Cellular Level By Lower Expression of Nucleoside Metabolizing Enzymes. Blood, 2016, 128, 5129-5129.	1.4	0
277	Effect of Lenalidomide (LEN) Exposure on Response and Outcomes in Patients (Pts) with Lower-Risk Non-Del(5q) Myelodysplastic Syndromes (MDS). Blood, 2016, 128, 3190-3190.	1.4	0
278	Pretreatment symptom prevalence in patients with myelodysplastic syndromes (MDS) across all disease risk categories: Analysis of 914 patients.. Journal of Clinical Oncology, 2019, 37, e18220-e18220.	1.6	0
279	I-Care for MDS: Development of Guidelines-Based Indicators for Appropriate Care in Adult Patients with Myelodysplastic Syndromes. Blood, 2019, 134, 4752-4752.	1.4	0
280	A Sex-Informed Approach to Improve Prognostication and Personalized Decision-Making Process in Myelodysplastic Syndromes. a European Study of 11.878 Patients. Blood, 2020, 136, 23-24.	1.4	0
281	Treatment of Lower Risk Myelodysplastic Syndromes. Hemato, 2022, 3, 153-162.	0.6	0
282	Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies. Hematological Oncology, 2022, 40, 491-504.	1.7	0